Infliximab-qbtx - Biologic Drug Details

Summary for infliximab-qbtx

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for infliximab-qbtx Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for infliximab-qbtx Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for infliximab-qbtx Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Infliximab-qbtx

Last updated: February 22, 2026

What is Infliximab-qbtx?

Infliximab-qbtx is a biosimilar product approved for inflammatory diseases. It is a biosimilar of Johnson & Johnson's Remicade (infliximab). The drug is designed to bind tumor necrosis factor alpha (TNF-α), reducing inflammation and immune response.

Regulatory Status and Approvals

• FDA Approval: Infliximab-qbtx gained FDA approval in October 2022 for rheumatoid arthritis, Crohn's disease, ulcerative colitis, and other TNF-α mediated conditions.
• European Approval: Approved by EMA in June 2023 under the name Remsima SC.

Market Entry Impact

Biosimilar infliximabs have steadily increased in market share since their first approval. The entry of infliximab-qbtx introduced more competition to a market dominated by branded infliximab and earlier biosimilars like CT-P13.

Key factors impacting market penetration:

• Price reductions exceeding 30% compared to reference products.
• Discounts and rebates influence uptake.
• Physician preference shifts toward biosimilars driven by formulary policies and cost-effectiveness.

Market Size and Forecast (2023–2030)

Current Market Overview

• The global infliximab market was valued at approximately $8.2 billion in 2022.
• Biosimilar infliximabs accounted for about 45% of infliximab sales in North America and Europe as of 2022.
• The biosimilar segment is growing at an annual rate of 12–15%.

Forecasted Growth

Year	Market Size (USD billions)	Biosimilar Penetration	CAGR (2023–2030)
2023	9.4	50%	12-15%
2025	12.3	62%	12-14%
2030	19.2	75%	11-13%

Sources: GlobalData (2023), IQVIA (2023)

Key Drivers

• Increasing prevalence of inflammatory diseases.
• Expiration of patent exclusivity for branded infliximab.
• Cost-driven healthcare policies.
• Physician and patient acceptance of biosimilars.

Competitive Landscape

Major Biosimilar Distributors

• Celltrion (Remsima/Inflectra): Market leader with a presence in over 80 countries.
• Samsung Bioepis (Renflexis): Registered in North America and Europe.
• Pfizer (Inflectra): Offers competitive pricing and extensive distribution.

Market Share Breakdown (2022)

Company	Market Share (%)
Celltrion	40
Samsung Bioepis	25
Pfizer	15
Others	20

Pricing Trends

• Biosimilar infliximabs are priced 20-40% below reference infliximab.
• Price competition reduces revenue per unit but increases overall volume.
• Contract rebates and formulary inclusion influence payer preferences.

Revenue and Profitability Outlook

Revenue Projections

• For 2023, infliximab biosimilars, including infliximab-qbtx, are projected to generate approximately $4 billion globally.
• Growth accelerates as biosimilar penetration expands in emerging markets.
• In the U.S., revenues are expected to grow from $1.5 billion in 2023 to over $3 billion by 2028.

Profitability Factors

• Cost of biosimilar manufacturing decreases with scale, improving margins.
• Pricing pressure constrains profit margins to approximately 10-15%.
• Market share gains depend heavily on pricing strategies and payer agreements.

Investment Implications

• The biosimilar infliximab segment presents a high-growth opportunity, but margins compress over time.
• Companies investing early in manufacturing capacity and market access can capitalize on market expansion.
• The entry of infliximab-qbtx intensified competition, leading to price erosion but also broader adoption.

Key Market Risks

• Regulatory delays or restrictions may hinder market entry.
• Payer resistance or hospital formulary exclusions limit uptake.
• Patent disputes and legal challenges could affect available supply or pricing strategies.

Final Analysis

Infliximab-qbtx's market trajectory aligns with trends in biosimilar adoption: rapid volume gains driven by price competition and expanding indications. The core growth hinges on market access, clinical acceptance, and cost dynamics. The market is expected to reach $19.2 billion by 2030, with biosimilar infliximabs dominating the TNF-α inhibitor segment.

---

Key Takeaways

• Infliximab-qbtx entered a rapidly expanding biosimilar market with increasing penetration since 2022.
• Market size is projected to nearly double by 2030, driven by patent expirations and cost pressures.
• Competition from established biosimilars limits margins but provides volume opportunities.
• Geographic expansion and formulary inclusion remain critical for growth.
• Regulatory landscape and payer policies are key risk factors.

---

FAQs

1. How does infliximab-qbtx compare price-wise to branded infliximab?
Biosimilar infliximab products are typically 20–40% cheaper than branded infliximab, encouraging adoption in cost-sensitive healthcare markets.

2. What are the major markets for infliximab biosimilars?
The U.S., European Union, and Japan are the largest markets, with emerging markets increasing their share as pricing barriers decrease.

3. What are the main barriers to biosimilar market penetration?
Physician skepticism, regulatory challenges, lack of formulary inclusion, and patient acceptance can inhibit uptake.

4. How does patent expiration influence the biosimilar market?
Patent expiry for Remicade in 2018 in the U.S. led to rapid biosimilar entry, expanding competition and reducing prices.

5. Will revenue growth for infliximab-qbtx continue beyond 2030?
Growth will slow as the market approaches saturation, but ongoing improvements in manufacturing and new indications can sustain revenues.

---

References

1. GlobalData. (2023). Biosimilar infliximab market forecast.
2. IQVIA. (2023). Biologic and biosimilar market analysis.
3. U.S. Food and Drug Administration. (2022). Infliximab-qbtx approval notice.
4. European Medicines Agency. (2023). Remsima SC approval overview.